세계의 지속적 신대체요법(CRRT) 시장 예측(-2028년) : 제품, 모달리티, 연령, 최종사용자, 지역별

Continuous Renal Replacement Therapy Market by Product (Hemofilter, Bloodline, Machines, Dialysates), Modality (SCUF, CVVH, CVVHD, CVVHDF), Age (Adult, Pediatric), Enduser (Hospitals, Ambulatory), and Region - Global Forecast to 2028

US $ 4,950 ￦ 6,877,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,238,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,322,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,893,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 지속적 신대체요법(CRRT) 시장 규모는 2023년 14억 달러에서 예측 기간 중 8.1%의 CAGR로 추이하며, 2028년에는 21억 달러 규모로 성장할 것으로 예측됩니다.

조사 범위
조사 대상년	2021-2028년
기준년	2022년
예측 기간	2023-2028년
단위	달러
부문	제품·모달리티·연령층·최종사용자·지역별
대상 지역	북미·유럽·아시아태평양·라틴아메리카·중동 & 아프리카

급성 신부전(AKI) 증가, 중환자실 및 중증 환자에서 효과적인 신장 대체 요법에 대한 관심 증가 등 다양한 요인이 CRRT 시스템 및 일회용품 수요 증가의 주요 요인으로 작용하고 있습니다. 또한 기술적으로 진보된 CRRT 시스템, 고혈압 유병률 증가, 급성 신장 질환 증가 등도 예측 기간 중 CRRT 수요를 촉진할 것으로 예상됩니다.

제품별로는 투석액 및 보충제 부문이 예측 기간 중 가장 큰 점유율을 차지할 것으로 예상되며, 예측 기간 중 높은 성장률을 기록할 것으로 전망됩니다. 높은 성장의 배경에는 혈행동태적으로 불안정한 환자 치료에서 CRRT에 대한 수요가 크게 증가하고, 신장 대체 요법을 위한 투석액 및 보충액을 제공하는 제조업체 증가, 그리고 시장 참여 기업의 강력한 존재감 등이 있습니다.

양식별로는 CVVHDF 부문이 예측 기간 중 가장 높은 성장률을 보일 것으로 예상됩니다. CVVHDF는 신장내과 전문의와 중환자 치료 의사들이 선호하는 경향이 있으며, 혈액투석에 비해 중간 크기의 용질을 잘 제거할 수 있다는 장점(중재 없이도 정확한 산염기 평형을 얻을 수 있고, CRRT와 관련된 인산 결핍 영역이 크게 감소하는 등)이 향후 몇 년간 이 분야의 성장 요인으로 작용할 것으로 보입니다. 향후 수년간 이 분야의 성장을 지원하는 요인 중 일부가 되고 있습니다.

지역별로는 아시아태평양이 예측 기간 중 가장 높은 CAGR로 성장할 것으로 예상되며, CRRT에 대한 인식 증가, 의료비 증가, 가처분 소득 증가, 패혈증 발생률 증가, AKI의 주요 원인인 고혈압과 당뇨병의 유병률 증가, 호주와 일본에서의 CRRT의 높은 CRRT 사용률, AKI 치료를 위한 CRRT 접근성 증가 등이 이 지역의 CRRT 시스템 도입 증가에 큰 역할을 하고 있습니다.

세계의 지속적 신대체요법(CRRT) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술·특허 동향, 사례 연구, 법규제 환경, 시장 규모의 추이·예측, 각종 구분·지역별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
  • 과제
• 규제 분석
• 상환 시나리오
• 주요 컨퍼런스와 이벤트
• 특허 분석
• 무역 분석
• 기술 분석
• 에코시스템 분석
• 밸류체인 분석
• 가격 동향 분석
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• CRRT 시스템에서 AI의 통합
• CRRT 시스템에 의한 미충족 요구와 최종사용자 기대

제6장 지속적 신대체요법(CRRT) 시장 : 제품별

• 투석액·보액
• 일회용품
  • 혈액 필터
  • 혈액 회로 세트·튜브
  • 기타
• CRRT 시스템

제7장 지속적 신대체요법(CRRT) 시장 : 모달리티별

• CVVH
• CVVHDF
• CVVHD
• SCUF

제8장 지속적 신대체요법(CRRT) 시장 : 연령층별

• 성인
• 소아·신생아

제9장 지속적 신대체요법(CRRT) 시장 : 최종사용자별

• 병원
• 외래 진료
• 재택의료
• 기타

제10장 지속적 신대체요법(CRRT) 시장 : 지역별

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제11장 경쟁 구도

• 개요
• 시장 참여 기업의 매출 점유율 분석
• 기업 평가 매트릭스
• 스타트업/중소기업의 기업 평가 매트릭스
• CRRT 시장에서 기업의 발자국 분석
• CRRT 시장 : 제품 발매와 규제기관 승인
• CRRT 시장 : 거래
• CRRT 시장 : 기타 개발

제12장 기업 개요

• 주요 기업
  • BAXTER INTERNATIONAL, INC.
  • FRESENIUS MEDICAL CARE AG & CO. KGAA
  • NIKKISO CO., LTD.
  • B. BRAUN MELSUNGEN AG
  • MEDTRONIC PLC
  • ASAHI KASEI CORPORATION
  • TORAY MEDICAL CO., LTD.
  • NIPRO CORPORATION
  • INFOMED SA
  • MEDICA SPA
  • MEDITES PHARMA SPOL. S.R.O.
  • MEDICAL COMPONENTS, INC.
  • SWS HEMODIALYSIS CARE CO., LTD.
  • NINGBO TIANYI MEDICAL DEVICES CO., LTD.
  • ANJUE MEDICAL EQUIPMENT CO., LTD.
  • KIMAL
  • JIANGXI SANXIN MEDTEC CO., LTD.
• 기타 기업
  • ALLMED MEDICAL PRODUCTS CO., LTD.
  • DIALCO MEDICAL INC.
  • BROWNDOVE HEALTHCARE PVT. LTD.
  • STERIS PLC
  • KURARAY MEDICAL PLC
  • LIVANOVA PLC
  • DIAVERUM DEUTSCHLAND GMBH
  • SEMBCORP INDUSTRIES

제13장 부록

KSA

영문 목차

영문목차

The global Continuous renal replacement therapy therapy market size is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 8.1% during the forecast period.

Scope of the Report
Years Considered for the Study	2021-2028
Base Year	2022
Forecast Period	2023-2028
Units Considered	(USD) billion
Segments	Product, modality, age group, End user and region
Regions covered	North America, EuropeAPAC, LATAM , MEA.

Various factors such as increasing incidences of Acute kidney injyury (AKI) and rising prominence on effective renal replacement therapy among patients in ICU and critically ill patients are majorly attributing to the rise in the demand for CRRT system and disposables. Moreover, the technologically advanced CRRT system in the market and rising prevalence of hypertension and rising cases of Acute kidney injury, are some of the factors which are anticipated to drive the demand for Continuous renal replacement therapy therapy during the forecast period.

"The dialysate and replacement fluid segment to capture the largest share in Continuous renal replacement therapy therapy market, by product, during the forecast period."

The dialysate and replacement fluid segment is expected to witness the high growth rate during the forecast period. The high growth owes to the significant increase in the demand for CRRT in the treatment for the patients who are unstablehemodynamically , the increase in the number of manufacturers who are offering dialysate and replacement fluids for renal replacement therapy, and also the strong presence of players in the market.

"The continuous venovenous hemodiafiltration segment to witness highest growth rate in Continuous renal replacement therapy therapy market, by modality in 2022."

The continuous venovenous hemodiafiltration modality segment is expected to witness the highest growth rate in the CRRT market during the forecast period. The rising preference of continuous venovenous hemodiafiltrationmodality among nephrologists and critical care physicians, and also the advantages which includes better clearance of medium-sized solutes in comparison to hemodialysis (accurate acid-base balance without intervention, and a significant reduction in CRRT-related phosphate depletion area are some of the factors which supports the growth of the segment in the coming years.

"The Hospital segment accounted for the largest share of the Continuous renal replacement therapy therapy, by age group, in 2022"

The CRRT process mainly adopted in hospitals due to its technological advancements and cost of investment. The economical stability of hospitals among other end users has led to its larger market share. The continuous renal replacement therapy (CRRT) is mostly used treatment in hospitals, especially in the intensive care unit (ICU) or the patients who are critically ill. It can help to stabilize hemodynamic parameters and improve clinical symptoms and organ function in patients, which can help to reduce complications

"The Asia Pacific market to grow at the highest CAGR during the forecast period."

The Continuous renal replacementtherapy market is segmented into five major regions, , North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The increase in the awareness of Continuous renal replacement therapy therapy, increasing healthcare expenditures, rising of the disposable incomes , rising incidences of sepsis, increasing prevalence of hypertension & diabetes (major causes of AKI), the high use of CRRT in Australia and Japan, , and increasing accessibility to CRRT for AKI treatment are some of the key factors that are playing major role in increase of adoption of the CRRT systems in Asia Pacific region

Breakdown of supply-side primary interviews:

• By Company Type: Tier 1: 25%, Tier 2: 30%, and Tier 3: 45%
• By Designation: C-level: 26%, D-level: 30%, and Others: 44%
• By Region: North America: 40%, Europe: 31%, APAC: 20%, Latin America: 6%, and the Middle East & Africa: 3%

The major players operating in the Continuous renal replacement therapy therapy market are Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International Inc. (US), and B. Braun Melsungen AG (Germany),

Research Coverage

This report studies the Continuous renal replacement therapy therapy market based on the product, modality, age group, end users and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Key Benefits of Buying the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

• Market Driver: The growth of the market attributes to increase of advanced technology and benefits of using CRRT systems.
• Market Penetration: Comprehensive information on the product portfolios of the top players in the Continuous renal replacement therapy market. The report analyzes the market based on the product, modality, age group, end users and region.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the Continuous renal replacement therapy market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for Continuous renal replacement therapy across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the Continuous renal replacement therapy market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the Continuous renal replacement therapy market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • FIGURE 1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: REGIONAL SEGMENTATION
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY
• 1.5 MAJOR MARKET STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES
• 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 2 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
  • FIGURE 3 PRIMARY SOURCES
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Insights from industry experts
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
• 2.2 MARKET SIZE ESTIMATION
  • FIGURE 7 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: BAXTER INTERNATIONAL INC.
  • FIGURE 9 REVENUE SHARE ANALYSIS FOR TOP PLAYERS
  • FIGURE 10 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • FIGURE 11 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY CONSUMABLES
  • FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET (2023-2028)
  • FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 14 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
  • FIGURE 15 DATA TRIANGULATION METHODOLOGY
• 2.4 RESEARCH ASSUMPTIONS
• 2.5 RISK ASSESSMENT
  • TABLE 1 RISK ASSESSMENT: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
• 2.6 LIMITATIONS
• 2.7 METHODOLOGY-RELATED LIMITATIONS
• 2.8 RECESSION IMPACT

3 EXECUTIVE SUMMARY

• FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
• FIGURE 17 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2023 VS. 2028 (USD MILLION)
• FIGURE 18 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2023 VS. 2028 (USD MILLION)
• FIGURE 19 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
• FIGURE 20 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS RENAL REPLACEMENT THERAPY MARKET

4 PREMIUM INSIGHTS

• 4.1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW
  • FIGURE 21 RISING PREVALENCE OF ACUTE KIDNEY INJURY AND GROWING AWARENESS OF CRRT TO DRIVE MARKET
• 4.2 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT AND COUNTRY (2022)
  • FIGURE 22 DIALYSATE & REPLACEMENT FLUIDS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
• 4.3 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 23 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
• 4.4 REGIONAL MIX: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET (2021-2028)
  • FIGURE 24 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
• 4.5 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: EMERGING VS. DEVELOPED MARKETS
  • FIGURE 25 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 26 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing incidence of acute kidney injury (AKI)
  • FIGURE 27 GLOBAL INCIDENCE OF ACUTE KIDNEY INJURY, 2010 VS. 2015 VS. 2020
  • TABLE 2 NUMBER OF PEOPLE AGED 65 OR OVER, BY REGION, 2019 VS. 2050
    • 5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis
  • FIGURE 28 IMPACT OF ICU-ACQUIRED AKI IN US
    • 5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification
    • 5.2.1.4 Technological advancements and new product launches
    • 5.2.1.5 Growing prevalence of diabetes and hypertension
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent regulatory guidelines in North America
    • 5.2.2.2 High procedural cost of CRRT
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emerging markets in Asia Pacific and RoW
    • 5.2.3.2 Increasing applications of CRRT
      • 5.2.3.2.1 Evolution of CRRT from simple renal replacement treatment to multi-organ support therapy
      • 5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines
    • 5.2.3.3 Ongoing research to establish safety and efficacy profile of CRRT
    • 5.2.3.4 Development of CRRT systems for pediatric patients
      • 5.2.3.4.1 The CARPEDIEM Project
    • 5.2.3.5 Untapped growth opportunities in North America
  • 5.2.4 CHALLENGES
    • 5.2.4.1 High complexity of CRRT
    • 5.2.4.2 Lack of standard treatment guidelines in developing nations
    • 5.2.4.3 Shortage of trained ICU professionals in developing nations
    • 5.2.4.4 Poor reimbursement scenario in developing countries
    • 5.2.4.5 Lack of awareness about benefits of CRRT
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 NORTH AMERICA
  • 5.3.2 EUROPE
  • 5.3.3 ASIA PACIFIC
    • 5.3.3.1 India
    • 5.3.3.2 China
    • 5.3.3.3 Japan
    • 5.3.3.4 South Korea
  • 5.3.4 REST OF THE WORLD (ROW)
    • 5.3.4.1 Brazil
    • 5.3.4.2 Argentina
• 5.4 REIMBURSEMENT SCENARIO
  • 5.4.1 NORTH AMERICA
  • 5.4.2 EUROPE
  • 5.4.3 ASIA PACIFIC
    • 5.4.3.1 Japan
  • 5.4.4 REST OF THE WORLD (ROW)
    • 5.4.4.1 Brazil
    • 5.4.4.2 Central America and the Caribbean
• 5.5 KEY CONFERENCES & EVENTS
  • TABLE 3 KEY CONFERENCES & EVENTS, 2023
• 5.6 PATENT ANALYSIS
  • 5.6.1 PATENT PUBLICATION TRENDS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • FIGURE 29 PATENT PUBLICATION TRENDS (JANUARY 2013-AUGUST 2023)
  • 5.6.2 INSIGHTS ON JURISDICTION AND TOP APPLICANT ANALYSIS
  • FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013-2023
  • FIGURE 31 TOP 10 APPLICANT COUNTRIES/REGIONS FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013-2023
  • TABLE 4 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: LIST OF MAJOR PATENTS
• 5.7 TRADE ANALYSIS
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 MINIMALLY INVASIVE CRRT
  • 5.8.2 CRRT IN COMBINATION WITH OTHER THERAPIES
• 5.9 ECOSYSTEM ANALYSIS
• 5.10 VALUE CHAIN ANALYSIS
  • FIGURE 32 VALUE CHAIN OF CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
• 5.11 PRICING TREND ANALYSIS
  • TABLE 5 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD)
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT OF NEW ENTRANTS
  • 5.12.2 THREAT OF SUBSTITUTES
  • 5.12.3 BARGAINING POWER OF SUPPLIERS
  • 5.12.4 BARGAINING POWER OF BUYERS
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • TABLE 7 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • 5.13.2 BUYING CRITERIA
  • FIGURE 34 KEY BUYING CRITERIA FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • TABLE 8 KEY BUYING CRITERIA FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
• 5.14 ARTIFICIAL INTELLIGENCE INTEGRATION IN CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS
• 5.15 UNMET NEED & END-USER EXPECTATIONS WITH CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS

6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
  • TABLE 9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
• 6.2 DIALYSATE & REPLACEMENT FLUIDS
  • 6.2.1 RISING DEMAND FOR DIALYSATE TO DRIVE MARKET
  • TABLE 10 DIALYSATE & REPLACEMENT FLUIDS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.3 DISPOSABLES
  • TABLE 11 DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 12 DISPOSABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3.1 HEMOFILTERS
    • 6.3.1.1 Widely adopted during CRRT procedures for treatment of AKI
  • TABLE 13 HEMOFILTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3.2 BLOODLINE SETS & TUBES
    • 6.3.2.1 Development of blood tubing with special coding to prevent clotting to offer growth opportunities
  • TABLE 14 BLOODLINE SETS & TUBES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3.3 OTHER DISPOSABLES
  • TABLE 15 OTHER DISPOSABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.4 CRRT SYSTEMS
  • 6.4.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED, EASY-TO-USE SYSTEMS TO BOOST MARKET GROWTH
  • TABLE 16 CRRT SYSTEMS MARKET BY COUNTRY, 2021-2028 (USD MILLION)

7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY

• 7.1 INTRODUCTION
  • TABLE 17 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
• 7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION
  • 7.2.1 WIDESPREAD ADOPTION IN TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET
  • TABLE 18 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION
  • 7.3.1 USED IN PATIENTS WITH CONGESTIVE HEART FAILURE
  • TABLE 19 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS
  • 7.4.1 MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES COMPARED TO OTHER CRRT MODALITIES
  • TABLE 20 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.5 SLOW CONTINUOUS ULTRAFILTRATION
  • 7.5.1 DOES NOT USE DIALYSATE OR REPLACEMENT FLUIDS FOR REMOVAL OF EXCESS FLUID FROM BLOODSTREAM
  • TABLE 21 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP

• 8.1 INTRODUCTION
  • TABLE 22 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
• 8.2 ADULTS
  • 8.2.1 LARGEST AND FASTEST-GROWING SEGMENT OF MARKET
  • TABLE 23 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR ADULTS, BY COUNTRY, 2021-2028 (USD MILLION)
• 8.3 PEDIATRICS & NEONATES
  • 8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO SUPPORT MARKET GROWTH
  • TABLE 24 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR PEDIATRICS & NEONATES, BY COUNTRY, 2021-2028 (USD MILLION)

9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER

• 9.1 INTRODUCTION
  • TABLE 25 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
• 9.2 HOSPITALS
  • 9.2.1 FASTEST-GROWING END-USER SEGMENT
  • TABLE 26 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
• 9.3 AMBULATORY CARE
  • 9.3.1 REDUCED INPATIENT STAY TO SUPPORT MARKET GROWTH
  • TABLE 27 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR AMBULATORY CARE, BY COUNTRY, 2021-2028 (USD MILLION)
• 9.4 HOME CARE
  • 9.4.1 RISING ADOPTION OF PORTABLE AND HOME-BASED DEVICES TO AID MARKET GROWTH
  • TABLE 28 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR HOME CARE, BY COUNTRY, 2021-2028 (USD MILLION)
• 9.5 OTHER END USERS
  • TABLE 29 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

10 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION

• 10.1 INTRODUCTION
  • TABLE 30 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION, 2021-2028 (USD MILLION)
• 10.2 NORTH AMERICA
  • 10.2.1 NORTH AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
  • FIGURE 35 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT
  • TABLE 31 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 32 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 33 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 34 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 35 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 36 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2.2 US
    • 10.2.2.1 Large number of AKI patients to drive market
  • TABLE 37 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 38 US: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 39 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 40 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 41 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2.3 CANADA
    • 10.2.3.1 High cost of CRRT to negatively impact market growth
  • TABLE 42 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 43 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 44 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 45 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 46 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.3 EUROPE
  • 10.3.1 EUROPEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
  • TABLE 47 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 48 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 49 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 50 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 51 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 52 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.2 GERMANY
    • 10.3.2.1 Largest market for continuous renal replacement therapy in Europe
  • TABLE 53 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 54 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 55 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 56 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 57 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.3 UK
    • 10.3.3.1 Rising number of sepsis cases to support market growth
  • TABLE 58 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 59 UK: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 60 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 61 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 62 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.4 FRANCE
    • 10.3.4.1 Growing AKI patient population to propel market growth
  • TABLE 63 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 64 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 65 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 66 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 67 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.5 ITALY
    • 10.3.5.1 Government initiatives to promote awareness of renal care to drive market
  • TABLE 68 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 69 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 70 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 71 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 72 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.6 SPAIN
    • 10.3.6.1 Favorable reimbursement scenario to favor market growth
  • TABLE 73 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 74 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 75 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 76 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 77 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3.7 REST OF EUROPE
  • TABLE 78 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 79 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 80 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 81 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 82 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.4 ASIA PACIFIC
  • 10.4.1 ASIA PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
  • FIGURE 36 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT
  • TABLE 83 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 85 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4.2 JAPAN
    • 10.4.2.1 Well-established medical infrastructure to support market growth
  • TABLE 89 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 90 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 91 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 92 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 93 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4.3 CHINA
    • 10.4.3.1 Increasing prevalence of ESRD and AKI to boost demand for CRRT
  • TABLE 94 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 95 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 96 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 97 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 98 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4.4 INDIA
    • 10.4.4.1 Large patient population to support market growth
  • TABLE 99 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 100 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 101 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 102 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 103 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Government initiatives to increase adoption of CRRT
  • TABLE 104 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 105 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 106 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 107 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 108 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Increasing awareness through online education programs and events to aid market growth
  • TABLE 109 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 110 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 111 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 112 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 113 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4.7 REST OF ASIA PACIFIC
  • TABLE 114 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 115 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 116 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 117 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 118 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.5 LATIN AMERICA
  • 10.5.1 LATIN AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
  • TABLE 119 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 120 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 121 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 122 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 123 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 124 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5.2 BRAZIL
    • 10.5.2.1 Rising incidence of AKI to drive market
  • TABLE 125 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 126 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 127 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 128 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 129 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5.3 MEXICO
    • 10.5.3.1 Large patient population to drive market
  • TABLE 130 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 131 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 132 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 133 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 134 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5.4 REST OF LATIN AMERICA
  • TABLE 135 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 136 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 137 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 138 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 139 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN MARKET GROWTH
  • 10.6.2 MIDDLE EAST AND AFRICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
  • TABLE 140 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • TABLE 141 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 142 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2028 (USD MILLION)
  • TABLE 143 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2028 (USD MILLION)
  • TABLE 144 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
  • FIGURE 37 GROWTH STRATEGIES ADOPTED BY KEY PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
• 11.2 REVENUE SHARE ANALYSIS OF MARKET PLAYERS, 2018-2022 (USD MILLION)
  • FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • FIGURE 39 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
  • TABLE 145 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEGREE OF COMPETITION
• 11.3 COMPANY EVALUATION MATRIX
  • 11.3.1 STARS
  • 11.3.2 EMERGING LEADERS
  • 11.3.3 PERVASIVE PLAYERS
  • 11.3.4 PARTICIPANTS
  • FIGURE 40 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022
• 11.4 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
  • 11.4.1 PROGRESSIVE COMPANIES
  • 11.4.2 STARTING BLOCKS
  • 11.4.3 RESPONSIVE COMPANIES
  • 11.4.4 DYNAMIC COMPANIES
  • FIGURE 41 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
• 11.5 FOOTPRINT ANALYSIS OF PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • TABLE 146 PRODUCT, REGIONAL, AND END-USER FOOTPRINT ANALYSIS OF PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
  • TABLE 147 PRODUCT FOOTPRINT OF COMPANIES
  • TABLE 148 END-USER FOOTPRINT OF COMPANIES
  • TABLE 149 REGIONAL FOOTPRINT OF COMPANIES
• 11.6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2019 TO AUGUST 2023)
  • TABLE 150 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
• 11.7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEALS (JANUARY 2019 TO AUGUST 2023)
  • TABLE 151 KEY DEALS
• 11.8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2019 TO AUGUST 2023)
  • TABLE 152 OTHER KEY DEVELOPMENTS

12 COMPANY PROFILES

• (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
• 12.1 MAJOR PLAYERS
  • 12.1.1 BAXTER INTERNATIONAL, INC.
  • TABLE 153 BAXTER INTERNATIONAL, INC.: BUSINESS OVERVIEW
  • FIGURE 42 BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
  • TABLE 154 BAXTER INTERNATIONAL, INC.: PRODUCT OFFERINGS
  • 12.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA
  • TABLE 155 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW
  • FIGURE 43 FRESENIUS MEDICAL CARE AG & CO. KGAA: COMPANY SNAPSHOT (2022)
  • TABLE 156 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS
  • 12.1.3 NIKKISO CO., LTD.
  • TABLE 157 NIKKISO CO., LTD.: BUSINESS OVERVIEW
  • FIGURE 44 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
  • TABLE 158 NIKKISO CO., LTD.: PRODUCT OFFERINGS
  • 12.1.4 B. BRAUN MELSUNGEN AG
  • TABLE 159 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
  • FIGURE 45 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2022)
  • TABLE 160 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS
  • 12.1.5 MEDTRONIC PLC
  • TABLE 161 MEDTRONIC PLC: BUSINESS OVERVIEW
  • FIGURE 46 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
  • TABLE 162 MEDTRONIC PLC: PRODUCT OFFERINGS
  • 12.1.6 ASAHI KASEI CORPORATION
  • TABLE 163 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
  • FIGURE 47 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
  • TABLE 164 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS
  • 12.1.7 TORAY MEDICAL CO., LTD.
  • TABLE 165 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW
  • FIGURE 48 TORAY MEDICAL CO., LTD.: COMPANY SNAPSHOT (2022)
  • TABLE 166 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS
  • 12.1.8 NIPRO CORPORATION
  • TABLE 167 NIPRO CORPORATION: BUSINESS OVERVIEW
  • FIGURE 49 NIPRO CORPORATION: COMPANY SNAPSHOT (2022)
  • TABLE 168 NIPRO CORPORATION: PRODUCT OFFERINGS
  • 12.1.9 INFOMED SA
  • TABLE 169 INFOMED SA: BUSINESS OVERVIEW
  • TABLE 170 INFOMED SA: PRODUCT OFFERINGS
  • 12.1.10 MEDICA SPA
  • TABLE 171 MEDICA SPA: BUSINESS OVERVIEW
  • TABLE 172 MEDICA SPA: PRODUCT OFFERINGS
  • 12.1.11 MEDITES PHARMA SPOL. S.R.O.
  • TABLE 173 MEDITES PHARMA SPOL. S.R.O.: BUSINESS OVERVIEW
  • TABLE 174 MEDITES PHARMA SPOL. S.R.O.: PRODUCT OFFERINGS
  • 12.1.12 MEDICAL COMPONENTS, INC.
  • TABLE 175 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW
  • TABLE 176 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS
  • 12.1.13 SWS HEMODIALYSIS CARE CO., LTD.
  • TABLE 177 SWS HEMODIALYSIS CARE CO., LTD.: BUSINESS OVERVIEW
  • TABLE 178 SWS HEMODIALYSIS CARE CO., LTD.: PRODUCT OFFERINGS
  • 12.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD.
  • TABLE 179 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW
  • TABLE 180 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS
  • 12.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD.
  • TABLE 181 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW
  • TABLE 182 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS
  • 12.1.16 KIMAL
  • TABLE 183 KIMAL: BUSINESS OVERVIEW
  • TABLE 184 KIMAL.: PRODUCT OFFERINGS
  • 12.1.17 JIANGXI SANXIN MEDTEC CO., LTD.
  • TABLE 185 JIANGXI SANXIAN MEDTECH CO., LTD.: BUSINESS OVERVIEW
  • TABLE 186 JIANGXI SANXIAN MEDTECH CO., LTD.: PRODUCT OFFERINGS
• 12.2 OTHER PLAYERS
  • 12.2.1 ALLMED MEDICAL PRODUCTS CO., LTD.
  • 12.2.2 DIALCO MEDICAL INC.
  • 12.2.3 BROWNDOVE HEALTHCARE PVT. LTD.
  • 12.2.4 STERIS PLC
  • 12.2.5 KURARAY MEDICAL PLC
  • 12.2.6 LIVANOVA PLC
  • 12.2.7 DIAVERUM DEUTSCHLAND GMBH
  • 12.2.8 SEMBCORP INDUSTRIES
• *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS

관련자료